Collaring Wolfe: Propoxyphene Moves Activist Back To Public Supplicant Role
Executive Summary
For almost four decades, one of the most painful public relations challenges for drug companies has been the need to respond quickly to surprise petitions from Public Citizen's Health Research Group asking FDA to withdraw a drug for an alleged safety issue
You may also be interested in...
Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote
Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.
Public Citizen's FDA? Lurie Is Consumer Group's Third In Key Agency Role
FDA's appointment of a high-profile consumer advocate to an Office of the Commissioner post continues a strategy of bringing some of the most outspoken critics of both the drug industry and its regulatory agency into FDA
Public Citizen's FDA? Lurie Is Consumer Group's Third In Key Agency Role
FDA's appointment of a high-profile consumer advocate to an Office of the Commissioner post continues a strategy of bringing some of the most outspoken critics of both the drug industry and its regulatory agency into FDA